Yuhan
As of the edition of 20 October 2026, Yuhan runs 51 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 9 |
| Went quiet | 23 |
| Stopped | 1 |
| Status not established | 15 |
| Total | 51 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lazertinib | Ends 2038 (patent) | 0 |
| Bilastine | none listed | 2 |
| Dapoxetine | none listed | 1 |
A route B row is one company at one target.
Where its trials are
- Lungs and airways: 13 trials led
- Cancer: 10 trials led
- Heart and blood vessels: 10 trials led